P1.12A.06 A Phase II 80 Mg Osimertinib in Patients with Leptomeningeal Metastases Associated with EGFR Mutation-Positive NSCLC (BLOSSOM)

• DOI: 10.1016/j.jtho.2024.09.352
• Publication Date: 2024-10-16T02:43:20Z
• Authors: S. Park; R. Baldry; H.A. Jung; J.-M. Sun; S.-H. Lee; J.S. Ahn; Y.J. Kim; Y. Lee; D.-W. Kim; S.-W. Kim; K.H. Lee; W.J. Lee; J.W. Choi; K. Chong; J.-I. Lee; S.-H. Gwon; N.-H. Son; M.-J. Ahn; J. Kim